The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Two endocrinologists who live with type 1 diabetes debate this issue at the Advanced Technologies & Treatments for Diabetes ...

By Miguel Solivan, Marketing Manager, Avery Dennison Medical Medical wearable devices, such as continuous glucose monitors ...

Wearable health technology enhances preventive care, enabling continuous monitoring of vital signs and proactive disease management for better health outcomes.